BioAtla, Inc. (BCAB)
1.26
-0.06
(-4.55%)
USD |
OTCM |
Sep 08, 16:00
BioAtla Debt to Equity Ratio : -0.1618 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1618 |
| March 31, 2026 | -0.1633 |
| December 31, 2025 | -0.2858 |
| September 30, 2025 | -0.1979 |
| June 30, 2025 | -0.361 |
| March 31, 2025 | 1.013 |
| December 31, 2024 | 0.0586 |
| September 30, 2024 | 0.0545 |
| June 30, 2024 | 0.053 |
| March 31, 2024 | 0.0387 |
| December 31, 2023 | 0.0348 |
| September 30, 2023 | 0.0301 |
| June 30, 2023 | 0.0259 |
| March 31, 2023 | 0.0231 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0221 |
| September 30, 2022 | 0.0305 |
| June 30, 2022 | 0.0285 |
| March 31, 2022 | 0.0265 |
| December 31, 2021 | 0.0255 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.0038 |
| March 31, 2021 | 0.0035 |
| December 31, 2020 | 0.0032 |
| September 30, 2020 | -1.335 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -0.3238 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 9.506M |
| Total Liabilities (Quarterly) | 45.74M |
| Shareholders Equity (Quarterly) | -36.24M |
| Current Ratio | 0.2026 |
| Net Debt Paydown Yield | -15.42% |